Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC)
The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy of metastatic renal cell carcinoma (mRCC). The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical pract...
Gespeichert in:
| Veröffentlicht in: | Annals of the Academy of Medicine, Singapore Singapore, 2015-10, Vol.44 (10), p.406-414 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 414 |
|---|---|
| container_issue | 10 |
| container_start_page | 406 |
| container_title | Annals of the Academy of Medicine, Singapore |
| container_volume | 44 |
| creator | Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup The Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup |
| description | The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy of metastatic renal cell carcinoma (mRCC).
The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.
Six international guidelines were evaluated- those developed by the National Comprehensive Cancer Network (2014), the European Association for Urology (2013), the European Society of Medical Oncology (2012), the National Institute of Health and Clinical Excellence (2011), the Canadian Kidney Cancer Forum (2013) and the Asian Oncology Summit (2012). Recommendations on the first-, second- and third-line treatment for mRCC were developed.
These adapted guidelines form the SCAN Guidelines 2015 for systemic therapy of mRCC. |
| doi_str_mv | 10.47102/annals-acadmedsg.V44N10p406 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760910725</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760910725</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-fee3e350557333875cefb1e329a0e094b007007e54ddfd4536930f5dd0838e9d3</originalsourceid><addsrcrecordid>eNpNkE1Lw0AQhhdRbK3-BdmDh_aQOsnuZhPwUoJWQSu01WvYZic12ny4myD99y62VmGYGebz5SHkyocxlz4E16qq1MZ6KlO6RG3X41fOZz40HMIj0gcG3OMhBMf_8h45s_YdgEsIwlPSC0IZMhBRnxSLolqrpjZIE1VlaOgM26_afNDhIpnMRnTaFRo3RYWW5rWhi61tsSwyunxDo5otrXP6hK2yrWpddY5OG01w45wyWVHVpaLDcp4ko3NykjvdeLGPA_Jyd7tM7r3H5-lDMnn0MiZl6-WIDJkAISRjLJIiw3zlIwtiBQgxXwFIZyi41rnmgoUxg1xoDRGLMNZsQIa7u42pPzu0bVoWNnOKVIV1Z1NfhhD7IAPhRm92o5mprTWYp40pSmW2qQ_pD-x0Bzs9wE7_YLv1y_2nbuWah-VfuuwbZcl_ww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760910725</pqid></control><display><type>article</type><title>Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC)</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup ; The Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</creator><creatorcontrib>Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup ; The Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</creatorcontrib><description>The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy of metastatic renal cell carcinoma (mRCC).
The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.
Six international guidelines were evaluated- those developed by the National Comprehensive Cancer Network (2014), the European Association for Urology (2013), the European Society of Medical Oncology (2012), the National Institute of Health and Clinical Excellence (2011), the Canadian Kidney Cancer Forum (2013) and the Asian Oncology Summit (2012). Recommendations on the first-, second- and third-line treatment for mRCC were developed.
These adapted guidelines form the SCAN Guidelines 2015 for systemic therapy of mRCC.</description><identifier>ISSN: 0304-4602</identifier><identifier>EISSN: 0304-4602</identifier><identifier>DOI: 10.47102/annals-acadmedsg.V44N10p406</identifier><identifier>PMID: 26763058</identifier><language>eng</language><publisher>Singapore</publisher><subject>Angiogenesis Inhibitors - therapeutic use ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab - administration & dosage ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - secondary ; Everolimus - therapeutic use ; Humans ; Imidazoles - therapeutic use ; Indazoles - therapeutic use ; Indoles - therapeutic use ; Interferon-alpha - administration & dosage ; Interleukin-2 - therapeutic use ; Kidney Neoplasms - pathology ; Kidney Neoplasms - surgery ; Nephrectomy ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Phenylurea Compounds - therapeutic use ; Pyrimidines - therapeutic use ; Pyrroles - therapeutic use ; Singapore ; Sirolimus - analogs & derivatives ; Sirolimus - therapeutic use ; Sulfonamides - therapeutic use</subject><ispartof>Annals of the Academy of Medicine, Singapore, 2015-10, Vol.44 (10), p.406-414</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-fee3e350557333875cefb1e329a0e094b007007e54ddfd4536930f5dd0838e9d3</citedby><cites>FETCH-LOGICAL-c377t-fee3e350557333875cefb1e329a0e094b007007e54ddfd4536930f5dd0838e9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26763058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</creatorcontrib><creatorcontrib>The Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</creatorcontrib><title>Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC)</title><title>Annals of the Academy of Medicine, Singapore</title><addtitle>Ann Acad Med Singapore</addtitle><description>The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy of metastatic renal cell carcinoma (mRCC).
The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.
Six international guidelines were evaluated- those developed by the National Comprehensive Cancer Network (2014), the European Association for Urology (2013), the European Society of Medical Oncology (2012), the National Institute of Health and Clinical Excellence (2011), the Canadian Kidney Cancer Forum (2013) and the Asian Oncology Summit (2012). Recommendations on the first-, second- and third-line treatment for mRCC were developed.
These adapted guidelines form the SCAN Guidelines 2015 for systemic therapy of mRCC.</description><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab - administration & dosage</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - secondary</subject><subject>Everolimus - therapeutic use</subject><subject>Humans</subject><subject>Imidazoles - therapeutic use</subject><subject>Indazoles - therapeutic use</subject><subject>Indoles - therapeutic use</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - surgery</subject><subject>Nephrectomy</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Niacinamide - therapeutic use</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Pyrroles - therapeutic use</subject><subject>Singapore</subject><subject>Sirolimus - analogs & derivatives</subject><subject>Sirolimus - therapeutic use</subject><subject>Sulfonamides - therapeutic use</subject><issn>0304-4602</issn><issn>0304-4602</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE1Lw0AQhhdRbK3-BdmDh_aQOsnuZhPwUoJWQSu01WvYZic12ny4myD99y62VmGYGebz5SHkyocxlz4E16qq1MZ6KlO6RG3X41fOZz40HMIj0gcG3OMhBMf_8h45s_YdgEsIwlPSC0IZMhBRnxSLolqrpjZIE1VlaOgM26_afNDhIpnMRnTaFRo3RYWW5rWhi61tsSwyunxDo5otrXP6hK2yrWpddY5OG01w45wyWVHVpaLDcp4ko3NykjvdeLGPA_Jyd7tM7r3H5-lDMnn0MiZl6-WIDJkAISRjLJIiw3zlIwtiBQgxXwFIZyi41rnmgoUxg1xoDRGLMNZsQIa7u42pPzu0bVoWNnOKVIV1Z1NfhhD7IAPhRm92o5mprTWYp40pSmW2qQ_pD-x0Bzs9wE7_YLv1y_2nbuWah-VfuuwbZcl_ww</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</creator><creator>The Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC)</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-fee3e350557333875cefb1e329a0e094b007007e54ddfd4536930f5dd0838e9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab - administration & dosage</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - secondary</topic><topic>Everolimus - therapeutic use</topic><topic>Humans</topic><topic>Imidazoles - therapeutic use</topic><topic>Indazoles - therapeutic use</topic><topic>Indoles - therapeutic use</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - surgery</topic><topic>Nephrectomy</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Niacinamide - therapeutic use</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Pyrroles - therapeutic use</topic><topic>Singapore</topic><topic>Sirolimus - analogs & derivatives</topic><topic>Sirolimus - therapeutic use</topic><topic>Sulfonamides - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</creatorcontrib><creatorcontrib>The Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the Academy of Medicine, Singapore</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><aucorp>Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</aucorp><aucorp>The Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC)</atitle><jtitle>Annals of the Academy of Medicine, Singapore</jtitle><addtitle>Ann Acad Med Singapore</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>44</volume><issue>10</issue><spage>406</spage><epage>414</epage><pages>406-414</pages><issn>0304-4602</issn><eissn>0304-4602</eissn><abstract>The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy of metastatic renal cell carcinoma (mRCC).
The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.
Six international guidelines were evaluated- those developed by the National Comprehensive Cancer Network (2014), the European Association for Urology (2013), the European Society of Medical Oncology (2012), the National Institute of Health and Clinical Excellence (2011), the Canadian Kidney Cancer Forum (2013) and the Asian Oncology Summit (2012). Recommendations on the first-, second- and third-line treatment for mRCC were developed.
These adapted guidelines form the SCAN Guidelines 2015 for systemic therapy of mRCC.</abstract><cop>Singapore</cop><pmid>26763058</pmid><doi>10.47102/annals-acadmedsg.V44N10p406</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-4602 |
| ispartof | Annals of the Academy of Medicine, Singapore, 2015-10, Vol.44 (10), p.406-414 |
| issn | 0304-4602 0304-4602 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760910725 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Angiogenesis Inhibitors - therapeutic use Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - secondary Everolimus - therapeutic use Humans Imidazoles - therapeutic use Indazoles - therapeutic use Indoles - therapeutic use Interferon-alpha - administration & dosage Interleukin-2 - therapeutic use Kidney Neoplasms - pathology Kidney Neoplasms - surgery Nephrectomy Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - therapeutic use Pyrimidines - therapeutic use Pyrroles - therapeutic use Singapore Sirolimus - analogs & derivatives Sirolimus - therapeutic use Sulfonamides - therapeutic use |
| title | Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A17%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Singapore%20Cancer%20Network%20(SCAN)%20Guidelines%20for%20Systemic%20Therapy%20of%20Metastatic%20Renal%20Cell%20Carcinoma%20(mRCC)&rft.jtitle=Annals%20of%20the%20Academy%20of%20Medicine,%20Singapore&rft.aucorp=Singapore%20Cancer%20Network%20(SCAN)%20Genitourinary%20Cancer%20Workgroup&rft.date=2015-10-01&rft.volume=44&rft.issue=10&rft.spage=406&rft.epage=414&rft.pages=406-414&rft.issn=0304-4602&rft.eissn=0304-4602&rft_id=info:doi/10.47102/annals-acadmedsg.V44N10p406&rft_dat=%3Cproquest_cross%3E1760910725%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760910725&rft_id=info:pmid/26763058&rfr_iscdi=true |